Blood Pressure and Mortality in Long-Term Hemodialysis Time to Move Forward

Size: px
Start display at page:

Download "Blood Pressure and Mortality in Long-Term Hemodialysis Time to Move Forward"

Transcription

1 Review Blood Pressure and Mortality in Long-Term Hemodialysis Time to Move Forward Panagiotis I. Georgianos 1 and Rajiv Agarwal 2 Contrary to the direct, graded, and causal relationship of hypertension with cardiovascular outcomes in the general population, among dialysis patients, blood pressure (BP) recorded either predialysis or postdialysis displays a U-shaped curve with mortality. This paradoxical phenomenon of lower BP or a decline in BP over time being associated with increased mortality and higher BP being associated with a lower mortality is described as reverse epidemiology of hypertension, raising substantial controversy on whether BP lowering causes harms or benefits among dialysis patients. Unlike the inverse relationship of peridialytic BP with mortality, elevated BP recorded outside of dialysis is directly associated with poor long-term outcomes. Apart from the timing and technique of BP measurement, the U-shaped association of BP with mortality is also modified when accounting for factors related to patient s clinical characteristics and level of illness, dialysis practices, and patterns as well as factors related to the methodology of survival analysis. Most importantly, deliberate BP lowering with antihypertensive drugs is associated with reduced cardiovascular morbidity and mortality. In this review, we explore the complex association of peridialytic, intradialytic, and interdialytic BP with outcomes among dialysis patients. We conclude with recommendations for a wider use of out-of-dialysis BP monitoring as a tool to better evaluate the cardiovascular risk and optimize the management of hypertension in this high-risk population. Rather than more cohort studies, we call for randomized trials to test the level of BP in dialysis patients that is optimal for cardiovascular outcomes. Keywords: ambulatory blood pressure monitoring; blood pressure; dialysis; epidemiology; hypertension; morbidity; mortality; randomized controlled trials. doi: /ajh/hpw114 Hypertension in end-stage renal disease patients on chronic dialysis is common, difficult to diagnose and often poorly controlled. 1,2 Unlike the direct and linear association of blood pressure (BP) with cardiovascular outcomes and mortality in the general population, cohort studies in dialysis patients showed an inverse relationship of BP recorded before or after dialysis with mortality. 3,4 The paradoxical phenomenon of lower BP being associated with poor long-term outcomes and higher BP being associated with a better outcome has been labeled as reverse epidemiology of hypertension, raising substantial uncertainty on whether hypertension is harmful and should be corrected in this particular population. 2 4 Contrary to the reverse prognostic association of conventional peridialytic BP recordings, elevated BP recorded outside of the dialysis unit either with self-measured home BP recordings or with 44-hour interdialytic ambulatory BP monitoring (ABPM) is directly associated with excess mortality risk. 5 7 In sharp contrast to the observational data, meta-analyses of randomized trials provided evidence that the risk of cardiovascular morbidity and mortality can be cut by a third when BP is lowered with the use of antihypertensive medications among dialysis patients, 8,9 particularly when they are hypertensive. 8 Thus, it appears that spontaneous changes in systolic BP carry with them a prognosis that is fundamentally different from lowering BP in a deliberate manner using antihypertensive drugs. In this review, we explore the reverse epidemiology of hypertension among patients on dialysis, discussing the role of confounding factors that magnify the inverse relationship of BP with mortality and oppose the ability of hypertension to predict risk. We compare this inverse relationship with the direct relationship of systolic BP lowering with an improvement in cardiovascular prognosis. We conclude with clinical practice recommendations for the necessity to widely apply the use of out-of-dialysis BP monitoring as an approach to better assess cardiovascular risk imposed by hypertension. We call for randomized trials, rather than more observational studies, to improve cardiovascular risk and optimize the management of hypertension among patients on dialysis. FACTORS THAT MAY EXPLAIN THE REVERSE RELATIONSHIP OF BP WITH MORTALITY The prognostic associations of BP recordings obtained before or after dialysis with cardiovascular outcomes and survival in numerous cohorts of incident and prevalent dialysis patients are summarized in Tables 1 and 2, respectively. The data suggest that lower predialysis BP is inversely associated with all-cause mortality On the other hand, Correspondence: Rajiv Agarwal (ragarwal@iu.edu). Initially submitted July 18, 2016; date of first revision August 26, 2016; accepted for publication August 26, 2016; online publication September 22, Division of Nephrology and Hypertension, First Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2 Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA. Published by Oxford University Press on behalf of American Journal of Hypertension Ltd This work is written by (a) US Government employees(s) and is in the public domain in the US. American Journal of Hypertension 30(3) March

2 Georgianos and Agarwal high-peridialytic BP recordings were either not associated or minimally associated with increased mortality risk This reverse or U-shaped association may be due to (i) the BP measurement setting and technique used to assess the hypertension status of study participants, 5 7,15 (ii) patient clinical characteristics and level of illness, (iii) the methodology used to the assess the value of hypertension as risk predictor in Cox-proportional hazard models. 11,14 These associations are discussed further. BP recordings obtained in-dialysis vs. out-of-dialysis provide different hazards with all-cause mortality Conventional BP measurements in the dialysis unit are inaccurate estimates of the true BP. Inaccurate determination of hypertension status with the use of conventional BP recordings obtained either predialysis or postdialysis leads to regression dilution bias, 3 limiting the ability of these measurements to provide clear and direct prognostic associations, even when such an association truly exists. Compared with nondialysis populations, BP among patients on dialysis is highly variable from predialysis to postdialysis as well as from 1 day to the next. 20 This high BP variability imposes particular difficulties in detecting hypertension with the use of peridialytic BP recordings; these measurements exhibit poor short-term reproducibility 21 and provide imprecise reflection of the actual BP burden recorded with the goldstandard method of 44-hour interdialytic ABPM. 22 Apart from their poor diagnostic accuracy in detecting interdialytic hypertension, another reason that could explain the reverse prognostic association of peridialytic BP with mortality is the fact that these measurements maybe influenced by the white-coat effect (i.e., elevated BP only in the dialysis setting), which is less pronounced with self-measured home BP recordings and eliminated with the use of interdialytic ABPM. 23,24 Another explanation could be that in-dialysis unit BP readings are unable to detect the masked hypertension effect (i.e., high BP at home and normal BP within dialysis), which may be also of prognostic significance. 24,25 Finally, BP recordings obtained shortly before or after dialysis maybe less representative of the patient s typical BP as compared with a pool of BP measurements sampled from a broader spectrum of situations and activities during the outof-dialysis period. 26 The notion that better precision in determination of hypertension status would provide direct and clear prognostic associations between BP and mortality is supported by a number of cohort studies using out-of-dialysis BP recordings as risk predictors (Table 3). In the first study to explore this hypothesis, Amar et al. 7 prospectively followed 57 French hypertensive dialysis patients for a mean period of 2.8 years. Each 10 mm Hg higher 24-hour pulse pressure (PP) recorded during the dialysis-off day was associated with 85% higher risk of cardiovascular mortality (risk ratio (RR): 1.85; 95% confidence interval (CI): ); nocturnal systolic hypertension was also an independent cardiovascular risk predictor (RR: 1.41; 95% CI: for each 10 mm Hg higher night-time systolic BP). 7 In a subsequent cohort of 168 Italian, nondiabetic dialysis patients without overt cardiovascular disease at baseline, an inverse night/day systolic BP ratio was associated with 2.52-fold higher risk of all-cause mortality (hazard ratio (HR): 2.52; 95% CI: ) and 4.33-fold higher risk of cardiovascular mortality (HR: 4.33; 95% CI: ) over 3.2 years of follow-up. 27 Among 73 Slovenian dialysis patients, Ekart et al. 28 reported that 16 patients died due to cardiovascular causes during a 10-year-long observational period. After adjustment for several conventional and nonconventional risk factors, mean 44-hour ambulatory BP was independently associated with increased risk of cardiovascular death. 28 Moriya et al. 29 prospectively evaluated 96 prevalent Japanese dialysis patients for a mean follow-up of 35 months to assess the endpoints of all-cause and cardiovascular mortality. Mean weekly PP (defined as the average of 14 BP measurements obtained by the patients themselves at home and 6 conventional peridialytic BP recordings) was calculated and used as fixed predictor in Kaplan Myer survival analysis. After multivariate adjustment, weekly averaged PP >70 mm Hg was independently associated with all-cause and cardiovascular mortality; in contrast, predialysis PP recorded in a single time-point had no association with either of the 2 outcomes. 29 The notion that the technique of measurement is likely to contribute to the variation in the association of BP with long-term outcomes is supported by 2 larger cohort studies, in which BP was assessed with self-monitored home BP recordings for 1 week, ABPM over a 44-hour interdialytic interval as well as predialysis and postdialysis for 6 consecutive dialysis sessions. 5,6 In the first, Alborzi et al. 6 showed that among 150 prevalent dialysis patients, each 1 standard deviation higher home systolic BP was associated with 35% increased risk of all-cause death (HR: 1.35; 95% CI: ) and 47% increased risk of cardiovascular death (HR: 1.47; 95% CI: ). 6 A similar relationship with mortality was detected when systolic BP was assessed by performing interdialytic ABPM (Figure 1). In the second, 326 prevalent dialysis patients were prospectively followed for a longer period of 32 months; 102 mortal events were recorded, yielding a crude mortality rate of 118/1000 patient-years. After multivariate adjustment, increasing quartiles of 44-hour ambulatory and self-measured home systolic BP were associated with increased risk of all-cause mortality (adjusted HRs for increasing quartiles of ambulatory systolic BP: 2.51, 3.43, 2.62; and for home systolic BP: 2.15, 1.7, 1.44). 5 Once again, BP recorded within the dialysis unit either with routine or with standardized measurements was of no prognostic significance. 5 Of importance, out-of-dialysis BP recordings retain their strong prognostic significance even when fewer randomly selected measurements are used to assess the BP burden. To test this hypothesis, Agarwal et al. 30 compared the associated mortality risk of mean 44-hour ambulatory BP with that of 6 BP recordings randomly selected from the same 44-hour ABPM in a cohort study of 133 dialysis patients. Over a mean follow-up of 24 months, the HRs for all-cause mortality were 1.22/1.18 per 10/5 mm Hg increase in mean 44-hour ambulatory BP and 1.20/1.15 when 6 BP recordings from the same ABPM were randomly selected and averaged. 30 This notion is also supported by a recent subanalysis of 326 incident dialysis patients participating in the Chronic Renal Insufficiency Cohort (CRIC) study. 15 In this 212 American Journal of Hypertension 30(3) March 2017

3 Epidemiology of Hypertension in Dialysis Table 1. Cohort studies evaluating the association of predialysis/postdialysis BP with mortality and clinical outcomes among incident dialysis patients Follow-up Author Year N Region (years) Age (years) Baseline BP (mm Hg) Association of BP with outcome (%) of patients on Pre-HD Post-HD antihypertensive therapy CVE/CVM ACM Tomita Japan /91 NA NA NA Reduction in SBP <160 mm Hg after the initiation of dialysis was associated with better 3-year survival Kimura Japan /91 NA NA NA No association between BP and ACM among patients with pre-existing cardiovascular disease Lynn New Zealand /81.5 NA 76% before dialysis initiation; only 4.5% continued antihypertensive therapy while on dialysis NA U-shaped association between MAP at commencement of dialysis and ACM Lucas Spain NA NA At the time of dialysis initiation, 36% had controlled hypertension and 37% uncontrolled hypertension Uncontrolled hypertension before initiation of HD was associated with increased risk of CVM (RR: 2.93; 95% CI: ) History of uncontrolled hypertension before the initiation of dialysis was an independent predictor of ACM (RR: 1.79; 95% CI: ) Stidley ,959 USA 34,705 personyears NA 151.8/ / NA Low pre-hd SBP (<120 mm Hg) was associated with increased risk of ACM at years 1 and 2 of dialysis; among dialysis patients who survived for >3 years, high pre-hd SBP (>150 mm Hg) was an independent predictor of ACM Lib ,338 USA / /74.4 NA NA Compared with the referent category mm Hg, pre-hd SBP <120 was associated with 3.19-fold higher risk of ACM (HR: 3.19; 95% CI: ) Myers ,283 USA 1.5 NA 150/78 NA NA NA U-shaped association between pre-hd SBP and ACM. This association was more pronounced among older patients and diabetics Shafi USA SBP: NA NA Among patients at lowrisk, pre-hd SBP was directly associated with increased risk of CVE (HR: 1.04; 95% CI: ) and CVM (HR: 1.10; 95% CI: ) The level of illness modified the association between pre-hd SBP and ACM. In the low-risk group, a linear association between pre-hd SBP and ACM was noted (HR: 1.07; 95% CI: ) Duranton France /71 NA 25.5 NA High-baseline pre-hd SBP was associated with 8% reduced risk of ACM (HR: 0.92; 95% CI: per 10 mm Hg increase) Abbreviations: ACM, all-cause mortality; BP, blood pressure; CI, confidence interval; CVE, cardiovascular events; CVM, cardiovascular mortality; DBP, diastolic blood pressure; HD, hemodialysis; HR, hazard ratio; MAP, mean arterial pressure; NA, not available; OR, odds ratio; RR, risk ratio; SBP, systolic blood pressure; SD, standard deviation. American Journal of Hypertension 30(3) March

4 Georgianos and Agarwal Table 2. Cohort studies evaluating the association of predialysis/postdialysis BP with mortality and clinical outcomes among prevalent dialysis patients Follow-up Author Year N Region (years) Age (years) Baseline BP (mm Hg) Association of BP with outcome (%) of patients on Pre-HD Post-HD antihypertensive therapy CVE/CVM ACM Charra France NA NA 1.6 Pre-HD MAP 99 mm Hg was associated with increased risk of CVM NA Salem USA 1 56 MAP: 110 NA 81.5 NA No association between pre-hd MAP and 1-year risk of ACM (RR: 0.99; 95% CI: ) Duranti Italy NA 53 NA NA NA NA Hypertension had no effect on ACM Iseki ,243 Japan /80.5 NA 51.7 NA Inverse association between DBP and ACM (OR: 0.84; 95% CI: ) Zager ,433 USA / / U-shaped association of BP with CVM; either low <110 (RR:2.04; 95% CI: ) or high post-hd SBP >180 mm Hg (RR: 1.73; 95% CI: ) were associated with increased CVM NA. Salem USA 2 56 MAP: 110 NA 81.5 NA Patients classified as hypertensives had a trend towards lower risk of ACM (RR: 0.73, P = 0.06) Blacher France /85 NA NA No significant association between DBP and CVM (HR: 0.90; 95% CI: ) Inverse association between DBP and ACM (HR: 0.60; 95% CI: ) Port ,499 USA NA NA NA NA Pre-HD SBP <110 mm Hg was associated with increased adjusted risk of ACM (RR: 1.86; 95% CI: ) Mazzuchi Uruguay /81 NA 45.2 NA Low pre-hd DBP <74.5 mmhg was associated with increased risk for early ACM (RR; 2.52, P = 0.004). High pre-hd SBP >160 mm Hg was associated with late ACM (RR: 2.19; P = 0.04) Tozawa ,243 Japan SBP: 151.5; DBP: 80.9; PP: 70.6 NA 52 Higher PP was associated with increased risk of CVE (HR: 1.138; 95% CI: ) in nondiabetic but not in diabetic HD patients. Higher PP was independent predictor of ACM (HR: 1.072; 95% CI: , P < 0.001) and cardiovascular events Klassen ,069 USA / /72.7 NA NA Inverse association between post-hd SBP and 1-year risk of ACM (HR: 0.87; 95% CI: ). Direct linear association between post-hd PP and ACM (HR: 1.12; 95% CI: ) Foley ,142 USA / / NA Increasing post-hd SBP was associated with increased ACM risk (HR: 3.00, P = 0.03) and increasing post-hd DBP with reduced risk of ACM (HR: 0.86, P = 0.006), 214 American Journal of Hypertension 30(3) March 2017

5 Epidemiology of Hypertension in Dialysis Table 2. Continued Follow-up Author Year N Region (years) Age (years) Baseline BP (mm Hg) Association of BP with outcome (%) of patients on Pre-HD Post-HD antihypertensive therapy CVE/CVM ACM Takeda Japan /82 NA 52 Elevated pre-hd SBP was independently associated with increased risk of CVE (RR: 1.23; 95% CI: ). and CVM (RR: 1.25; 95% CI: ) No association between pre-hd SBP and ACM. Kalantar ,933 USA /79 NA NA Inverse association between Zadeh 10 pre-hd SBP and CVM Lower pre-hd SBP (<110 mm Hg) was associated with 60% higher risk of ACM (HR: 1.60; 95% CI: ) Li ,590 USA 3 years / /71.5 NA NA A reverse J-shaped association of pre-hd SBP with 1-year and 3-year ACM risk. Low pre-hd SBP (<120 mm Hg) was associated with the highest risk for ACM (HR: 2.634; 95% CI: ) Ishimitsu Japan 5 years /81 NA 79.7 A linear association of pre-hd PP with CVM (HR: 1.023; 95% CI: ) A linear association of pre-hd PP with ACM (HR: 1.015; 95% CI: ) Molnar ,579 patients with PKD USA 5 years 58 NA NA NA NA Among patients with PKD, low pre-hd SBP <120 mm Hg (HR: 1.30; 95% CI: ) was associated with increased ACM risk. A similar J-shaped association was evident in 67,085 HD patients without PKD Chang ,846 patients participating in the HEMO study USA NA NA 79.1 NA Low pre-hd SBP (<120 mm Hg) was associated with 84% higher risk for ACM (HR: 1.84; 95% CI: , P < 0.001) Robinson ,525 patients participating in the DOPPS study USA 47,124 person- Europe years New Zealand Japan NA 150/78 NA NA NA Low pre-hd SBP mmhg was associated with increased risk of ACM (HR: 1.14; 95% CI: ). Higher pre-hd SBP mm Hg was associated with reduced risk of ACM (HR: 0.90, 95% CI: ) Losito ,674 Italy / / NA No association between BP and ACM in the overall study cohort. An inverse association between post-hd SBP and ACM among nontreated (HR: 0.74; 95% CI: ) Abbreviations: ACM, all-cause mortality; BP, blood pressure; CI, confidence interval; CVE, cardiovascular events; CVM, cardiovascular mortality; DBP, diastolic blood pressure; DOPPS, Dialysis Outcomes and Practice Patterns Study; HD, hemodialysis; HR, hazard ratio; MAP, mean arterial pressure; NA, not available; OR, odds ratio; PKD, polycystic kidney disease; RR, risk ratio; SBP, systolic blood pressure. American Journal of Hypertension 30(3) March

6 Georgianos and Agarwal study, in-dialysis unit systolic BP showed a U-shaped curve with mortality risk, in line with several previous cohorts of incident dialysis patients. 11,31,32 In contrast, when systolic BP was recorded during the dialysis-off day in a prespecified follow-up visit (in the office setting), a direct and linear association with all-cause mortality was evident (HR: 1.26; 95% CI: per 10 mm Hg higher systolic BP). 15 Notably, neither home BP monitoring nor ABPM was necessary to detect this diverse prognostic association of out-of-dialysis BP readings with mortality. Level of illness and severity of comorbidities modifies the relationship of BP and mortality The level of illness and the severity of comorbid conditions with opposing effect on BP may confound the role of hypertension as predictor of risk among dialysis patients. 3,4 In a longitudinal analysis of 4,499 prevalent dialysis patients participating in the Case-Mix Adequacy Study of the US Renal Data System (USRDS), Port et al. 12 showed that a low predialysis systolic BP of <110 mm Hg was associated with 86% higher risk of cardiovascular mortality (RR: 1.86; 95% CI: , P < 0.001). When the analysis was stratified according to the history of pre-existing heart disease, the risk of mortality associated with low predialysis systolic BP was 2.5-fold higher among those with congestive heart failure. 12 However, when neither coronary artery disease nor congestive heart failure was present, the risk for all-cause mortality was 1.5 and not statistically significant. Accordingly, this landmark cohort study suggests that the underlying history of congestive heart failure may modify the risk for all-cause mortality and systolic BP. To investigate the influence of age, race, and diabetes on the association of BP with mortality, Myers et al. 17 studied 16,283 dialysis patients initiating renal replacement therapy at facilities operated by a large not-for-profit dialysis care provider in the United States during They explored the association of age, diabetes, and race with outcomes. Age and systolic BP was modeled using cubic splines that allow the detection of nonlinear relationships of these continuous variables with all-cause mortality. An older age and the presence of diabetes magnified the association of low predialysis systolic BP with excess mortality. Among younger participants, a higher predialysis systolic BP was associated with increased mortality regardless of the diabetic status or race; in contrast, among older patients, high predialysis systolic BP was not predictive of risk. 17 In the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study, incident US dialysis patients were classified into a high- vs. a low-biomarker group according to the levels of cardiac troponin I (ctni 0.1 ng/ml) and N-terminal fragment of prohormone B-type natriuretic peptide (NT-proBNP 9,252 pg/ml). As expected, patients in the high-biomarker group were older, had more frequently history of pre-existing heart disease and had higher adjusted mortality risk relative to those classified in the low-biomarker group (HR: 1.75; 95% CI: ). 18 The presence of subclinical cardiovascular disease modified the prognostic significance of predialysis BP (P for interaction 0.01 for all-cause mortality, 0.2 for cardiovascular mortality, and 0.07 for first cardiovascular event). Increasing systolic BP was associated with greater risk of all-cause mortality (HR: 1.07; 95% CI: , P = 0.03) only among patients classified in the low-biomarker group. 18 In contrast, predialysis systolic BP was not associated with all-cause mortality in the high-biomarker group (HR: 0.99; 95% CI: , P = 0.70). Dialysis vintage confounds the relationship of BP and mortality Another source of confounding in the complex association of BP with mortality appears to be the dialysis vintage, i.e., time elapsed from onset of dialysis therapy. In a cohort of 405 patients who had survived at least 2 years on dialysis before the study enrollment, Mazzuchi et al. 16 explored the association of baseline BP with the risk of death during the first 2 years of follow-up (years 3 and 4 of dialysis, early mortality) and the risk of death after the second year of follow-up (>5 years on dialysis, late mortality). When early mortality was analyzed, patients with lower systolic BP of <110 mm Hg had 3.9-fold higher risk of death (RR: 3.91; 95% CI: ). In contrast, when late mortality was analyzed, systolic BP >160 mm Hg was the only independent predictor of mortality (RR: 2.42, P = 0.04). 16 This differentiation is possibly explained by the fact that the most frequent causes of early deaths were withdrawal of dialysis therapy and malignancies, whereas late mortality was predominantly due to cardiac diseases. 16 In a subsequent analysis of 16,959 incident dialysis patients in the United States, 19 low predialysis systolic BP of <120 mm Hg was associated with increased mortality risk in years 1 and 2 after dialysis initiation. In contrast, among patients who survived at least 3 years on dialysis, high-baseline systolic BP 150 mm Hg was associated with excess mortality. 19 It appears, therefore, that the assumption of proportionality inherent in the Cox models may be violated; early deaths among those with low systolic BP and late deaths among those with a higher systolic BP may point to distinct pathophysiological pathways. Modeling BP as a time-varying covariate The reverse association of low-peridialytic BP with increased mortality risk was shown to be more pronounced in cohort studies treating BP as a time-varying covariate in Cox-proportional hazard models. 3,4 In a cohort of 5,433 prevalent US dialysis patients prospectively followed over a mean follow-up of 2.6 years, Zager et al. 14 showed a U-shaped association of predialysis and postdialysis BP with mortality. When BP was modelled as fixed predictor, the RR for all-cause mortality attributable to low predialysis systolic BP of <110 mm Hg was 1.64 (95% CI: ). When BP was treated as a time-varying covariate, predialysis systolic BP of <110 mm Hg was associated with 3.07-fold increased risk of death (RR: 3.07; 95% CI: ). 14 In a larger cohort of 56,338 patients initiating dialysis therapy during in a large dialysis chain in the United States, 11 predialysis systolic BP showed again a 216 American Journal of Hypertension 30(3) March 2017

7 Epidemiology of Hypertension in Dialysis Table 3. Cohort studies evaluating the association of out-of-dialysis BP recordings with mortality and clinical outcomes among dialysis patients Follow-up Author Year N Region (years) Age (years) (%) of patients on antihypertensive therapy BP measurement technique Association of BP with outcome Amar France ABPM Higher 24-hour PP was associated with increased risk of CVM (RR: 1.85; 95% CI: ) and higher nighttime SBP with increased risk of CVM (RR: 1.41; 95% CI: ) Tripepi Italy ABPM Patients with night/day SBP ratio >1.01 had increased risk of ACM (HR: 2.52; 95% CI: ) and CVM (HR: 4.33; 95% CI: ) Alborzi USA HBPM Each 1 SD higher self-measured home SBP increased by 35% the risk of ACM (HR: 1.35; 95% CI: ) and ABPM by 47% the risk of cardiovascular death (HR: 1.47; 95% CI: ) Agarwal USA HBPM Mean 44-hour interdialytic ambulatory SBP (HR: 1.22; 95% CI: ) had the same prognostic significance for ABPM ACM with that of 6 randomly selected SBP recordings from the same ABPM (HR: 1.20; 95% CI: ) Moriya Japan HBPM Weekly averaged PP was an independent predictor of ACM Agarwal USA HBPM Increasing quartile of 44-hour ambulatory and home SBP were associated increased risk of ACM (adjusted HRs for ABPM increasing quartiles of ambulatory SBP: 2.51, 3.43, 2.62; and for home SBP: 2.15, 1.7, 1.44) Ekart Slovenia ABPM 44-hour ambulatory SBP and DBP independent predictors of CVM Bansal incident HD patients participating in the CRIC study 2.83 NA NA Out-of-dialysis BP measurement in a single visit U-shaped association between dialysis-unit SBP and ACM. A direct linear association between out-of-dialysis SBP and ACM (HR: 1.26; 95% CI: ). Abbreviations: ABPM, ambulatory blood pressure monitoring; ACM, all-cause mortality; BP, blood pressure; CI, confidence interval; CRIC, Chronic Renal Insufficiency Cohort study; CVM, cardiovascular mortality; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; HD, hemodialysis; HR, hazard ratio; NA, not available; SBP, systolic blood pressure. American Journal of Hypertension 30(3) March

8 Georgianos and Agarwal Figure 1. Out-of-dialysis BP recordings are of greater significance in predicting all-cause mortality among patients on dialysis. This figure depicts hazard ratios (HRs) for all-cause mortality for increasing quartiles of systolic BP. Increasing quartiles of home BP and ambulatory BP were associated with increased risk of mortality; in contrast, in-dialysis unit BP recordings did not achieve statistical significance in terms of prognostic value. Home systolic BP of mm Hg and of mm Hg by ambulatory BP was associated with the best prognosis in hemodialysis patients. Abbreviations: BP, blood pressure; HD, hemodialysis. (Reprinted with permission from Alborzi et al. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2: ) reverse J-shaped curve with 1-year mortality risk. The mortality risk for predialysis systolic BP of <120 mm Hg was 3.19 times higher when treated as fixed covariate and 6.27 times higher when treated as time-varying covariate. 11 It has to be noted, however, that the magnified mortality risk arising in time-varying Cox-regression models does not prove causality between the risk factor (hypertension) and the outcome (mortality). For example, if a hypertensive patient developed heart failure or another condition with opposing effect on BP, the effect of pre-existing hypertension on mortality would be diluted. 3,4 In contrast, interventional trials where BP is deliberately lowered with the use of antihypertensive agents consistently show cardiovascular protection (vide infra). Pulsatile BP component as predictor of risk The association of BP with mortality among dialysis patients is modified depending on the BP component used as predictor of risk in hazards models. 3,4 Analyzing systolic and diastolic BP in isolation may ignore the effect of the pulsatile BP component, which is a powerful predictor of risk both in the general population 33 and among people with chronic kidney disease. 34,35 The relationship between different BP components and all-cause mortality was evaluated in a Japanese cohort of 1,243 prevalent dialysis patients. 36 When BP components were considered individually, a positive association with allcause mortality was observed for PP (HR: 1.080, P = 0.002) and systolic BP (HR: 1.040, P = 0.04), but not for diastolic BP. When systolic and diastolic BP were considered conjointly, systolic BP was associated positively (HR: 1.083, P = 0.001) and diastolic BP inversely with all-cause mortality (HR: 0.086, P = 0.01), implying that widened PP is a strong and direct predictor of risk. 36 In a larger cohort of 11,142 prevalent dialysis patients participating in the USRDS Dialysis Morbidity and Mortality Waves 3 and 4 Study, Foley et al. 37 explored the prognostic significance of systolic and diastolic BP individually and conjointly in a Cox-proportional hazard model. A reverse association between BP and mortality was noted when systolic and diastolic BP components were considered in isolation. When considered conjointly, a direct association of systolic BP and an inverse association of diastolic BP with all-cause mortality emerged either predialysis or postdialysis. The HRs for all-cause mortality were 1.06/0.79 for predialysis BP and 3.0/0.87 for postdialysis BP (per 10 mm Hg increase in BP). 37 The association of PP with 1-year mortality risk was assessed in another cohort of 37,069 prevalent dialysis patients from a large dialysis chain in the United States. 38 After adjusting for level of systolic BP, a direct and linear association between increasing PP and increasing mortality risk was evident. Each 10 mm Hg increase in postdialysis PP increased by 12% the risk of death (HR: 1.12; 95% CI: ). 38 Taken together, the above associations of PP with poor long-term outcomes may reflect a state of accelerated arterial ageing, which is a potent cardiovascular risk predictor among people on chronic dialysis Although PP is informative as a prognostic marker, its value as a clinical measure to provide guidance with respect to clinical decision making is limited. Nonetheless, it should be recognized that for any given systolic BP in a patient on long-term dialysis a lower diastolic BP magnifies the risk for future mortality. Randomized evidence vs. observational data The reverse association of BP with all-cause and cardiovascular mortality seen in observational studies is contrasted by the results of 2 meta-analyses of randomized controlled trials showing that BP lowering with antihypertensive drug use confers cardiovascular risk reduction in dialysis patients. 8,9 The first meta-analysis included 8 randomized placebocontrolled trials incorporating data from 1,697 dialysis patients and 495 cardiovascular events. The weighted mean difference in the change of BP between the active-treatment and placebo groups during follow-up was 4.5 mm Hg for systolic and 2.3 mm Hg for diastolic BP. 9 This BP-lowering effect was associated with 29% reduction in the risk of all-cause mortality (pooled RR: 0.71; 95% CI: ) and 29% reduction in the risk of cardiovascular mortality (pooled RR: 0.71; 95% CI: ). 9 In the second, Agarwal et al. 8 included 5 randomized trials with 1,202 study participants. Compared with placebo or control therapy, the overall cardiovascular benefit of BP lowering with antihypertensive drug therapy was a 31% reduced risk of future cardiovascular events (pooled HR: 0.69; 95% CIs: ). The cardiovascular protection offered by BP lowering was lesser when normotensive patients were included in the analysis (pooled HR: 0.86; 95% CI: ) (Figure 2). 8 These interventional data are at variance 218 American Journal of Hypertension 30(3) March 2017

9 Epidemiology of Hypertension in Dialysis Figure 2. Effect of deliberate blood pressure (BP) lowering with antihypertensive drug therapy on cardiovascular events among patients on dialysis. The figure depicts the hazard ratios (HRs) of BP lowering with antihypertensive medications on cardiovascular events. The analysis was separated on the basis of the hypertension status of patients included in individual studies. Deliberate BP lowering was shown to confer cardiovascular protection among dialysis patients, particularly when they are hypertensive. (Reprinted with permission from Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53:860 6.) with the cohort studies but add to the growing body of evidence that hypertension among people on dialysis is harmful and should be controlled. INTRADIALYTIC HYPERTENSION AND MORTALITY Contrary to the typical decline in BP from predialysis to postdialysis, in approximately 10 15% of dialysis patients, BP exhibits a paradoxical intradialytic elevation. 43,44 The exact mechanisms responsible for this complex dialysis-related complication are not yet fully clear. In a post-hoc analysis of the Dry-weight Reduction In Hemodialysis Patients (DRIP) trial, it was shown that probing of dry-weight in those patients with intradialytic hypertension at study initiation resulted in significant reductions of both intradialytic and interdialytic BP, suggesting that intradialytic hypertension is a marker of volume excess and is associated with systemic background hypertension. 45 This notion is also supported by studies showing that patients experiencing intradialytic hypertension have significantly higher 44-hour ambulatory systolic and diastolic BP levels as compared with carefully matched patients without intradialytic hypertension. 46,47 This phenomenon has gained increased attention in light of recent cohort studies associating intradialytic hypertension with higher mortality risk (Table 4). In a post-hoc analysis of the Critic-Line Intradialytic Monitoring Benefit (CLIMB) trial, intradialytic hypertension (defined as a rise is systolic BP of >10 mm Hg from predialysis to postdialysis) was detected in 13.2% of study participants. 48 Compared with patients whose systolic BP fell with dialysis, those with intradialytic hypertension had 2.17-fold elevated risk of reaching the combined end-point of all-cause death and non-access-related hospitalization over 6 months of follow-up (odds ratio (OR): 2.17; 95% CI: ). 48 The association of intradialytic hypertension with 2-year survival was evaluated in a longitudinal analysis of 1,748 patients participating in the USRDS Dialysis Morbidity and Mortality Wave II study. 49 After controlling for several risk factors and postdialysis systolic BP levels, each 10 mm Hg increase in systolic BP from predialysis to postdialysis was associated with 12% excess risk of death (HR: 1.12; 95% CI: ). When the analysis was stratified depending on the levels of predialysis BP, intradialytic hypertension remained prognostically significant only in the subgroup of patients with predialysis systolic BP of 120 mm Hg or lower (HR: 1.12; 95% CI: ). 49 Another cohort study of 115 dialysis patients showed that a mean rise in systolic BP of >5 mm Hg during dialysis over 25 consecutive dialysis sessions was associated with 3.93-fold increased risk of allcause mortality (HR: 3.93; 95% CI: ). 50 In 2 recent large studies using Cox-regression hazard models with restricted cubic splines, it was shown that the magnitude of intradialytic change in BP displays a nonlinear association with mortality. 51,52 Among 113,255 prevalent patients from a large dialysis chain in the United States, Park et al. 52 reported that large intradialytic reductions in systolic BP of >30 mm Hg and rise in systolic BP from predialysis to postdialysis of any degree were both associated with increased mortality risk. Contrary to the above mentioned USRDS data, 49 the association of intradialytic hypertension with mortality was greater among patients with predialysis systolic BP of 120 mm Hg or higher. 52 This U-shaped curve was confirmed in a subsequent study enrolling 98,577 patients treated in facilities operated by a large dialysis care provider in the United States during Over American Journal of Hypertension 30(3) March

10 Georgianos and Agarwal Table 4. Cohort studies evaluating the association of intradialytic change in BP with mortality and clinical outcomes among dialysis patients Author Year N Region Follow-up Predictor Outcome Risk OR: 2.17; 95% CI: per 10 mm Hg increase in SBP during HD Combined end-point of nondialysisrelated hospitalization or ACM Inrig USA 6 months ΔSBP from pre- to post-hd 10 mm Hg ACM HR: 1.12; 95% CI: per 10 mm Hg increase in SBP during HD Inrig ,748 USA 2 years ΔSBP from pre- to post-hd ACM HR: 3.925; 95% CI: Yang Taiwan 4 years ΔSBP >5 mm Hg from pre- to post-hd ACM U-shaped association of ΔSBP during dialysis with ACM and CVM in Cox-regression analysis with restricted cubic splines CVM Park ,255 USA 2.2 years ΔSBP from pre- to post-hd ACM U-Shaped association between ΔPP during HD and ACM. Compared to the referent group of ΔPP < 5 to 5 mm Hg, those with ΔPP < 25 mm Hg had 21% higher risk of ACM (HR: 1.21; 95% CI: ) and those with ΔPP 25 mm Hg had 27% elevated risk of ACM (HR: 1.27; 95% CI: ) Lertdumrongluk ,577 USA NA Time-varying ΔPP from pre- to post-hd Abbreviations: ACM, all-cause mortality; CI, confidence interval; CVM, cardiovascular mortality; HD, hemodialysis; HR, hazard ratio; NA, not available; OR, odds ratio; ΔPP, change in pulse pressure; ΔSBP, change in systolic blood pressure. 134,814 patient-years of at-risk time, 16,054 (16%) patients died, yielding a crude all-cause mortality rate of 119/1000 patient-years. 51 In models adjusted for either predialysis systolic BP or mean arterial pressure, declines in PP of >25 mm Hg (HR: 1.26; 95% CI: ) as well as elevations in PP of >25 mm Hg (HR: 1.27; 95% CI: ) were both associated with increased risk of death. 51 This U-shaped curve persisted in the case-mix and malnutrition-inflammationcomplex syndrome adjusted hazard models. Whether the excess mortality risk among patients experiencing intradialytic hypertension is solely attributable to the pattern of hemodynamic response within dialysis or whether background systemic hypertension is also of prognostic significance remains unknown. This issue could be clarified by modeling the risk of intradialytic hypertension in analyses adjusted for the degree of 44-hour interdialytic ambulatory BP. If the predictive power of intradialytic hypertension for all-cause or cardiovascular mortality is mitigated after such an adjustment, background interdialytic hypertension would be the prominent contributor to the excess risk of death associated with this condition; 53 such an analysis is currently missing. CONCLUSION The inverse association of BP recorded before or after dialysis with all-cause and cardiovascular mortality had for long generated the notion that hypertension among people on dialysis is not harmful and should not be adequately controlled. Although, it is clear that systolic BP <110 mm Hg measured just prior to the initiation of dialysis, especially in a patient not being treated with antihypertensive agents, is a harbinger of poor outcomes, the theory of reverse epidemiology of hypertension in dialysis has fostered complacence in not treating those with volume excess and severe hypertension. It is now time to revisit reverse epidemiology in light of a growing body of evidence that indicates strongly and consistently that elevated BP recorded outside of dialysis provides a direct mortality signal. In dialysis patients more so than in any other population, the wide use of home and ABPM is expected to advance the prognostication of cardiovascular morbidity and mortality and improve management of hypertension. Given that currently available guideline recommendations for BP targets used in the general population as well as in people with chronic kidney disease not yet on dialysis are not applicable to those on maintenance dialysis, a high priority goal of future research is to identify the optimal thresholds at which BP should be targeted in these individuals. Since observational data do not provide cause-and-effect associations, randomized clinical trials using out-of-dialysis BP monitoring are urgently warranted to fully elucidate this critical gap in the existing knowledge. ACKNOWLEDGMENTS R.A. is supported by NIH 1 R01 HL A1 and a grant from VA Merit Review 5I01CX American Journal of Hypertension 30(3) March 2017

11 Epidemiology of Hypertension in Dialysis DISCLOSURE R.A. has served as an advisor for several pharmaceutical companies that make antihypertensive drugs including Merck, Takeda, Novartis, Daiichi Sankyo, Abbvie, Bayer, and Johnson and Johnson; P.I.G. has no conflicts of interest to disclose. REFERENCES 1. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol 2014; 25: Agarwal R. Exploring the paradoxical relationship of hypertension with mortality in chronic hemodialysis. Hemodial Int 2004; 8: Agarwal R. Hypertension and survival in chronic hemodialysis patients past lessons and future opportunities. Kidney Int 2005; 67: Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension 2010; 55: Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2: Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57: Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009; 53: Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Greenland S, Kopple JD. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58 th annual fall conference and scientific sessions. Hypertension 2005; 45: Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48: Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: Robinson BM, Tong L, Zhang J, Wolfe RA, Goodkin DA, Greenwood RN, Kerr PG, Morgenstern H, Li Y, Pisoni RL, Saran R, Tentori F, Akizawa T, Fukuhara S, Port FK. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2012; 82: Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P. U curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54: Bansal N, McCulloch CE, Rahman M, Kusek JW, Anderson AH, Xie D, Townsend RR, Lora CM, Wright J, Go AS, Ojo A, Alper A, Lustigova E, Cuevas M, Kallem R, Hsu CY; CRIC Study Investigators. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension 2015; 65: Mazzuchi N, Carbonell E, Fernández-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: Myers OB, Adams C, Rohrscheib MR, Servilla KS, Miskulin D, Bedrick EJ, Zager PG. Age, race, diabetes, blood pressure, and mortality among hemodialysis patients. J Am Soc Nephrol 2010; 21: Shafi T, Zager PG, Sozio SM, Grams ME, Jaar BG, Christenson RH, Boulware LE, Parekh RS, Powe NR, Coresh J. Troponin I and NT-proBNP and the association of systolic blood pressure with outcomes in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 2014; 64: Stidley CA, Hunt WC, Tentori F, Schmidt D, Rohrscheib M, Paine S, Bedrick EJ, Meyer KB, Johnson HK, Zager PG; Medical Directors of Dialysis Clinic Inc. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17: Rohrscheib MR, Myers OB, Servilla KS, Adams CD, Miskulin D, Bedrick EJ, Hunt WC, Lindsey DE, Gabaldon D, Zager PG; DCI Medical Directors. Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: Sinha AD, Agarwal R. Peridialytic, intradialytic, and interdialytic blood pressure measurement in hemodialysis patients. Am J Kidney Dis 2009; 54: Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol 2006; 1: Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45: Parati G, Ochoa JE, Bilo G, Agarwal R, Covic A, Dekker FW, Fliser D, Heine GH, Jager KJ, Gargani L, Kanbay M, Mallamaci F, Massy Z, Ortiz A, Picano E, Rossignol P, Sarafidis P, Sicari R, Vanholder R, Wiecek A, London G, Zoccali C; European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association- European Dialysis Transplantation Association (ERA-EDTA). Hypertension in chronic kidney disease part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. Hypertension 2016; 67: Johnson KA, Partsch DJ, Rippole LL, McVey DM. Reliability of selfreported blood pressure measurements. Arch Intern Med 1999; 159: Gerin W, Schwartz JE, Devereux RB, Goyal T, Shimbo D, Ogedegbe G, Rieckmann N, Abraham D, Chaplin W, Burg M, Jhulani J, Pickering TG. Superiority of ambulatory to physician blood pressure is not an artifact of differential measurement reliability. Blood Press Monit 2006; 11: Tripepi G, Fagugli RM, Dattolo P, Parlongo G, Mallamaci F, Buoncristiani U, Zoccali C. Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int 2005; 68: Ekart R, Kanič V, Pečovnik Balon B, Bevc S, Hojs R. Prognostic value of 48-hour ambulatory blood pressure measurement and cardiovascular mortality in hemodialysis patients. Kidney Blood Press Res 2012; 35: Moriya H, Oka M, Maesato K, Mano T, Ikee R, Ohtake T, Kobayashi S. Weekly averaged blood pressure is more important than a singlepoint blood pressure measurement in the risk stratification of dialysis patients. Clin J Am Soc Nephrol 2008; 3: Agarwal R, Andersen MJ, Light RP. Location not quantity of blood pressure measurements predicts mortality in hemodialysis patients. Am J Nephrol 2008; 28: Duranton F, Duny Y, Szwarc I, Deleuze S, Rouanet C, Selcer I, Maurice F, Rivory JP, Servel MF, Jover B, Brunet P, Daurès JP, Argilés À. Early changes in body weight and blood pressure are associated with mortality in incident dialysis patients. Clin Kidney J 2016; 9: Lynn KL, McGregor DO, Moesbergen T, Buttimore AL, Inkster JA, Wells JE. Hypertension as a determinant of survival for patients treated with home dialysis. Kidney Int 2002; 62: Haider AW, Larson MG, Franklin SS, Levy D; Framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2003; 138: American Journal of Hypertension 30(3) March

Hypertension is common among patients with chronic

Hypertension is common among patients with chronic Hemodialysis Blood Pressure and Mortality Among Hemodialysis Patients Rajiv Agarwal Abstract Blood pressure measured before and after dialysis does not agree well with those recorded outside the dialysis

More information

Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD

Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease. Rajiv Agarwal, MD Ambulatory Blood Pressure and Cardiovascular Events in Chronic Kidney Disease Rajiv Agarwal, MD Summary: Hypertension is an important risk factor for adverse cardiovascular and renal outcomes, particularly

More information

Intradialytic hypertension is a marker of volume excess

Intradialytic hypertension is a marker of volume excess Nephrol Dial Transplant (2010) 1 of 6 doi: 10.1093/ndt/gfq210 NDT Advance Access published April 16, 2010 Original Article Intradialytic hypertension is a marker of volume excess Rajiv Agarwal 1,2 and

More information

Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods

Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods DIALYSIS Blood Pressure Measurement and Left Ventricular Mass Index in Hemodialysis Patients Comparison of Several Methods Amir Ahamd Nassiri, 1 Legha Lotfollahi, 2,3 Neda Behzadnia, 4 Ilad Alavi Darazam,

More information

Strategies to assess and manage hypervolemia The invisible threat in dialysis

Strategies to assess and manage hypervolemia The invisible threat in dialysis Strategies to assess and manage hypervolemia The invisible threat in dialysis Rajiv Agarwal MD Professor of Medicine, Indiana University School of Medicine Volume excess is common and costly. Admission

More information

Blood Pressure Monitoring in Chronic Kidney Disease

Blood Pressure Monitoring in Chronic Kidney Disease Blood Pressure Monitoring in Chronic Kidney Disease Aldo J. Peixoto, MD FASN FASH Associate Professor of Medicine (Nephrology), YSM Associate Chief of Medicine, VACT Director of Hypertension, VACT American

More information

Which dialysis unit blood pressure is the most accurate for predicting home blood pressure in patients undergoing hemodialysis?

Which dialysis unit blood pressure is the most accurate for predicting home blood pressure in patients undergoing hemodialysis? ORIGINAL ARTICLE Korean J Intern Med 2017;32:117-124 Which dialysis unit blood pressure is the most accurate for predicting home blood pressure in patients undergoing hemodialysis? In-Cheol Yoon, Hye-Min

More information

Slide notes: References:

Slide notes: References: 1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory

More information

Diagnosing Hypertension by Intradialytic Blood Pressure Recordings

Diagnosing Hypertension by Intradialytic Blood Pressure Recordings Diagnosing Hypertension by Intradialytic Blood Pressure Recordings Rajiv Agarwal,* Tesfamariam Metiku,* Getachew G. Tegegne,* Robert P. Light,* Zerihun Bunaye,* Dagim M. Bekele,* and Ken Kelley *Division

More information

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University

Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Hypertension in Hemodialysis Patient Maher Fouad Ramzy; MD, FACP Professor of Renal Medicine, Cairo University Mechanism of HTN in HD patients Volume-dependent HTN ECV expansion. Volume-independent HTN

More information

Epidemiology/Population. Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis

Epidemiology/Population. Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis The Chronic Renal Insufficiency Cohort Study Nisha Bansal, Charles E. McCulloch, Mahboob Rahman, John

More information

Age-related Blood Pressure Patterns and Blood Pressure Variability among Hemodialysis Patients

Age-related Blood Pressure Patterns and Blood Pressure Variability among Hemodialysis Patients Age-related Blood Pressure Patterns and Blood Pressure Variability among Hemodialysis Patients Mark R. Rohrscheib,* Orrin B. Myers, Karen S. Servilla, Christopher D. Adams,* Dana Miskulin, Edward J. Bedrick,

More information

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

University of Padova, Padua, Italy, and HARVEST Study Group, Italy University of Padova, Padua, Italy, and HARVEST Study Group, Italy ISOLATED SYSTOLIC HYPERTENSION IN THE YOUNG DOES NOT IMPLY AN INCREASED RISK OF FUTURE HYPERTENSION NEEDING TREATMENT Mos L, Saladini

More information

Optimal blood pressure targets in chronic kidney disease

Optimal blood pressure targets in chronic kidney disease Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management

More information

HTA ET DIALYSE DR ALAIN GUERIN

HTA ET DIALYSE DR ALAIN GUERIN HTA ET DIALYSE DR ALAIN GUERIN Cardiovascular Disease Mortality General Population vs ESRD Dialysis Patients 100 Annual CVD Mortality (%) 10 1 0.1 0.01 0.001 25-34 35-44 45-54 55-64 66-74 75-84 >85 Age

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES

More information

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine

Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine Seung Hyeok Han, MD, PhD Department of Internal Medicine Yonsei University College of Medicine The Scope of Optimal BP BP Reduction CV outcomes & mortality CKD progression - Albuminuria - egfr decline

More information

Importance of Ambulatory Blood Pressure Monitoring in Adolescents

Importance of Ambulatory Blood Pressure Monitoring in Adolescents Importance of Ambulatory Blood Pressure Monitoring in Adolescents Josep Redon, MD, PhD, FAHA Internal Medicine Hospital Clinico Universitario de Valencia University of Valencia CIBERObn Instituto de Salud

More information

Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis Patients

Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis Patients Age, Race, Diabetes, Blood Pressure, and Mortality among Hemodialysis Patients Orrin B. Myers,* Christopher Adams,* Mark R. Rohrscheib,* Karen S. Servilla, Dana Miskulin, Edward J. Bedrick,* and Philip

More information

WHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington

WHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have

More information

Assessment and Management of Hypertension in Patients on Dialysis

Assessment and Management of Hypertension in Patients on Dialysis Assessment and Management of Hypertension in Patients on Dialysis Rajiv Agarwal,* Joseph Flynn, Velvie Pogue, Mahboob Rahman, Efrain Reisin, and Matthew R. Weir *Division of Nephrology, Department of Medicine,

More information

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES

The CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions

More information

Noor Naif Al-Hakami. Pharm-D candidate (KSU)

Noor Naif Al-Hakami. Pharm-D candidate (KSU) Hypertension In Hemodialysis Patients Treated With Atenolol Or Lisinopril: A Randomized Controlled Trial (Rajiv Agarwal, Arjun D. Sinha, Maria K. Pappas, Terri N. Abraham and Getachew G. Tegegne ) Noor

More information

Weekly Averaged Blood Pressure Is More Important than a Single-Point Blood Pressure Measurement in the Risk Stratification of Dialysis Patients

Weekly Averaged Blood Pressure Is More Important than a Single-Point Blood Pressure Measurement in the Risk Stratification of Dialysis Patients Weekly Averaged Blood Pressure Is More Important than a Single-Point Blood Pressure Measurement in the Risk Stratification of Dialysis Patients Hidekazu Moriya, Machiko Oka, Kyoko Maesato, Tsutomu Mano,

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

Hemodialysis. Volume-Associated Ambulatory Blood Pressure Patterns in Hemodialysis Patients. Rajiv Agarwal

Hemodialysis. Volume-Associated Ambulatory Blood Pressure Patterns in Hemodialysis Patients. Rajiv Agarwal Hemodialysis Volume-Associated Ambulatory Blood Pressure Patterns in Hemodialysis Patients Rajiv Agarwal Abstract Although volume excess causes hypertension, whether it also affects circadian patterns

More information

How is the dialysis patient different?

How is the dialysis patient different? How is the dialysis patient different? Mihály Tapolyai, MD, FASN, FACP Fresenius Medical Care SOTE, Budapest; Hungary Minneapolis VAMC, Minneapolis, MN; USA How is the dialysis patient different? Dialysis

More information

Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients

Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure patterns in hemodialysis patients Am J Physiol Renal Physiol 294: F303 F308, 2008. First published December 26, 2007; doi:10.1152/ajprenal.00575.2007. Arterial stiffness and interdialytic weight gain influence ambulatory blood pressure

More information

How well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study

How well do office and exercise blood pressures predict sustained hypertension? A Dundee Step Test Study (2000) 14, 429 433 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE How well do office and exercise blood pressures predict sustained hypertension?

More information

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained?

Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? O R I G I N A L A R T I C L E Long-term blood pressure monitoring and echocardiographic findings in patients with end-stage renal disease: reverse epidemiology explained? H. Borsboom 1#, L. Smans 1#, M.J.M.

More information

Diagnostic methods 2: receiver operating characteristic (ROC) curves

Diagnostic methods 2: receiver operating characteristic (ROC) curves abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager

More information

Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients

Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients ORIGINAL PAPER Comparison of 44-Hour and Fixed 24-Hour Ambulatory Blood Pressure Monitoring in Dialysis Patients Wenjin Liu, MD; Hong Ye, MD; Bing Tang, MD; Zhiping Sun, MD; Ping Wen, MD; Wenhui Wu, MD;

More information

Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice

Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice (2005) 19, 801 807 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Prognostic significance of blood pressure measured in the office, at home and

More information

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial

Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Blood Pressure Goal in Elderly Hypertensive Patients with Diabetes Mellitus: A Subanalysis of the CASE-J Trial Kenji Ueshima 1, Shinji Yasuno 1, Sachiko Tanaka 1, Akira Fujimoto 1, Toshio Ogihara 2, Takao

More information

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure

Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure 801 Original Article Nomogram of the Relation of Brachial-Ankle Pulse Wave Velocity with Blood Pressure Akira YAMASHINA, Hirofumi TOMIYAMA, Tomio ARAI, Yutaka KOJI, Minoru YAMBE, Hiroaki MOTOBE, Zydem

More information

Haemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health

Haemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different

More information

Dialysis outcomes: can we do better?

Dialysis outcomes: can we do better? Dialysis outcomes: can we do better? Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director, Chronic Disease Research Group Minneapolis Medical Research Foundation Director,

More information

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas

EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS KDIGO. Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas EPIDEMIOLOGY OF ARRHYTHMIAS AND OUTCOMES IN CKD & DIALYSIS Wolfgang C. Winkelmayer, MD, ScD Baylor College of Medicine Houston, Texas Disclosure of Interests AstraZeneca (scientific advisory board) Bayer

More information

Optimal blood pressure level and best measurement procedure in hemodialysis patients

Optimal blood pressure level and best measurement procedure in hemodialysis patients REVIEW Optimal blood pressure level and best measurement procedure in hemodialysis patients Annie Saint-Remy Jean-Marie Krzesinski Nephrology-Hypertension/Dialysis Unit, University Hospital of Liège, Liège,

More information

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen

More information

Post Hoc Analysis of the PARADIGM Heart Failure Trial:

Post Hoc Analysis of the PARADIGM Heart Failure Trial: Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming

More information

J-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial

J-curve Revisited. An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial J-curve Revisited An Analysis of Blood Pressure and Cardiovascular Events in the Treating to New Targets (TNT) Trial Sripal Bangalore, MD, MHA, Franz H Messerli, MD, Chuan-Chuan Wun, PhD, Andrea L. Zuckerman,

More information

Examining Facility Level Data

Examining Facility Level Data Examining Facility Level Data for the USRDS Yi Li, PhD Professor of Biostatistics, University of Michigan, Ann Arbor Director, Kidney Epidemiology and Cost Center (KECC) Co Deputy Director, United States

More information

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town

Hypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the

More information

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs

More information

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,

More information

AJNT. Original Article

AJNT. Original Article . 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin

More information

The effect of joint exposures: examining the presence of interaction

The effect of joint exposures: examining the presence of interaction http://www.kidney-international.org & 2009 International Society of Nephrology abc of epidemiology The effect of joint exposures: examining the presence of interaction Renée de Mutsert 1, Kitty J. Jager

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease

More information

Overview of the outcome trials in older patients with isolated systolic hypertension

Overview of the outcome trials in older patients with isolated systolic hypertension Journal of Human Hypertension (1999) 13, 859 863 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Overview of the outcome trials in older patients with isolated

More information

Long-term outcomes in nondiabetic chronic kidney disease

Long-term outcomes in nondiabetic chronic kidney disease original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,

More information

KDIGO Controversies Conference on Blood Pressure in CKD

KDIGO Controversies Conference on Blood Pressure in CKD KDIGO Controversies Conference on Blood Pressure in CKD September 7-10, 2017 Edinburgh, Scotland Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization whose mission is to improve

More information

UC Irvine UC Irvine Previously Published Works

UC Irvine UC Irvine Previously Published Works UC Irvine UC Irvine Previously Published Works Title A comparative effectiveness research study of the change in blood pressure during hemodialysis treatment and survival Permalink https://escholarship.org/uc/item/1d78m1rn

More information

CAD in Chronic Kidney Disease. Kuang-Te Wang

CAD in Chronic Kidney Disease. Kuang-Te Wang CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,

More information

가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine

가정혈압의활용 CARDIOVASCULAR CENTER. Wook Bum Pyun M.D., Ph.D. HOME BLOOD PRESSURE MONITORING. Ewha Womans University, school of Medicine 가정혈압의활용 HOME BLOOD PRESSURE MONITORING CARDIOVASCULAR CENTER Wook Bum Pyun M.D., Ph.D. pwb423@ewha.ac.kr Ewha Womans University, school of Medicine Non-Invasive Blood Pressure Measurement 5-20% Resistant

More information

SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section

SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section SpringerLink Header: Hypertension (WB White and AJ Peixoto, Section Editors) What Are Optimal Blood Pressure Targets for Patients with Hypertension and Chronic Kidney Disease? Gopesh K. Modi, MD DM 1,

More information

Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes

Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Original Investigation Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Eduardo Lacson Jr, MD, MPH, Weiling Wang, MS, Cari DeVries, Keith

More information

The association of body mass index (BMI) with mortality

The association of body mass index (BMI) with mortality Body Mass Index-Mortality Paradox in Hemodialysis Can It Be Explained by Blood Pressure? Rajiv Agarwal See Editorial Commentary, pp 989 990 Abstract Unlike the general population, among hemodialysis patients

More information

David C. Mendelssohn MD, FRCPC DOPPS Update 2010

David C. Mendelssohn MD, FRCPC DOPPS Update 2010 David C. Mendelssohn MD, FRCPC DOPPS Update 2010 Budapest Nephrology School August 30, 2010 Overview 1) General aspects of DOPPS 2) Facility based analysis 3) High hemoglobin 4) Coumadin use 5) Summary

More information

Treated ESRD Incidence Rate for Selected Countries, New Patients/Million Pop. 250 USA (All) USRDS 1996

Treated ESRD Incidence Rate for Selected Countries, New Patients/Million Pop. 250 USA (All) USRDS 1996 Annual Data Report International Comparisons of ESRD Therapy Chapter XI International Comparisons of ESRD Therapy O ver the last decade a growing number of national and regional registries dealing with

More information

Achieve. Achieve. More Effective. Dialysis Treatment

Achieve. Achieve. More Effective. Dialysis Treatment Achieve More Effective Achieve Dialysis Treatment The Crit-Line monitor measures the following: Real-time, lab-equivalent, non-invasive hematocrit (HCT) Real-time percent changes in intravascular blood

More information

Anirudh Rao a, David Pitcher a, Ken Farrington b

Anirudh Rao a, David Pitcher a, Ken Farrington b UK Renal Registry 16th Annual Report: Chapter 11 Blood Pressure Profile of Prevalent Patients receiving Renal Replacement Therapy in 2012: National and -specific Analyses Anirudh Rao a, David Pitcher a,

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 23 June 2016 EMA/CHMP/345847/2015 Committee for Medicinal products for Human Use Overview of comments received on ''Guideline on clinical investigation of medicinal products in the treatment of hypertension'

More information

USRDS UNITED STATES RENAL DATA SYSTEM

USRDS UNITED STATES RENAL DATA SYSTEM USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart

More information

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine RISE, FALL AND RESURRECTION OF RENAL DENERVATION Michael A. Weber, MD State University of New York Downstate College of Medicine Michael Weber, Disclosures Research/Trial Commitments and Consulting: Boston

More information

The problem of uncontrolled hypertension

The problem of uncontrolled hypertension (2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands

More information

IN THE LAST few decades, several important

IN THE LAST few decades, several important Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald

More information

Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices

Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices Original Articles Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices Naoki KIMATA, 1 Angelo KARABOYAS, 2 Brian A. BIEBER, 2 Ronald

More information

Lynsey Webb a, Charles RV Tomson b, Anna Casula a, Ken Farrington c

Lynsey Webb a, Charles RV Tomson b, Anna Casula a, Ken Farrington c Chapter 11 Blood Pressure Profile of Prevalent Patients receiving Renal Replacement Therapy in England, Wales and Northern Ireland in 09: national and centre-specific analyses Lynsey Webb a, Charles RV

More information

The monthly ESH guide through publications

The monthly ESH guide through publications NEWSLETTER APRIL 2016 The monthly ESH guide through publications Edited by: Prof Costas Tsioufis, ESH Secretary and Dr Alex Kasiakogias Effects of hypertension treatment on heart failure: insights from

More information

PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL

PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL PREVALENCE AND TYPES OF INTRA-DIALYTIC COMPLICATIONS IN PATIENTS DIALYSING AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL ADEJUMO OA, OLOKOR AB, IYAWE IO, OKAKA EI, UNUIGBE EI, OJOGWU LI Presented at Nigerian

More information

Chapter 2: Identification and Care of Patients With CKD

Chapter 2: Identification and Care of Patients With CKD Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease

More information

Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients

Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients J Am Soc Nephrol 13: 1061 1066, 2002 Dialysis Dose and Body Mass Index Are Strongly Associated with Survival in Hemodialysis Patients FRIEDRICH K. PORT, VALARIE B. ASHBY, RAJNISH K. DHINGRA, ERIK C. ROYS,

More information

Is Traditional Clinic Blood Pressure Dead?

Is Traditional Clinic Blood Pressure Dead? Royal College of Physicans May 16 th 2017 Is Traditional Clinic Blood Pressure Dead? Professor Bryan Williams MD FRCP FAHA FESC Chair of Medicine UCL Director National Institute for Health Research Biomedical

More information

Chapter 6: Mortality. Introduction 2016 USRDS ANNUAL DATA REPORT VOLUME 2 ESRD IN THE UNITED STATES

Chapter 6: Mortality. Introduction 2016 USRDS ANNUAL DATA REPORT VOLUME 2 ESRD IN THE UNITED STATES Chapter 6: Mortality In 2014, adjusted mortality rates for ESRD, dialysis, and transplant patients, were 136, 166, and 30, per 1,000 patient-years, respectively. By dialysis modality, mortality rates were

More information

24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting

24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting 2017 Dementia 24-uur ambulante bloeddrukmeting versus thuisbloedrukmeting Wat gebruiken in de klinische praktijk? Jan A. Staessen, MD, PhD KU Leuven jan.staessen@kuleuven.be BPM Key messages to be made

More information

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension http://www.kidney-international.org & 08 International Society of Nephrology original article see commentary on page 667 Achieving blood pressure targets during dialysis improves control but increases

More information

Left ventricular hypertrophy: why does it happen?

Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,

More information

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized

More information

Ambulatory arterial stiffness index as a predictor of cardiovascular events.

Ambulatory arterial stiffness index as a predictor of cardiovascular events. Ambulatory arterial stiffness index as a predictor of cardiovascular events. A meta-analysis of longitudinal studies. Konstantinos Aznaouridis, Charalambos Vlachopoulos, Christodoulos Stefanadis. 1 st

More information

TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA

TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA & TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia

More information

Blood Pressure Targets in Diabetes

Blood Pressure Targets in Diabetes Stockholm, 29 th August 2010 ESC Meeting Blood Pressure Targets in Diabetes Peter M Nilsson, MD, PhD Department of Clinical Sciences University Hospital, Malmö Sweden Studies on BP in DM2 ADVANCE RCT (Lancet

More information

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker

More information

Retour sur le congrès de l AHA 2017

Retour sur le congrès de l AHA 2017 Retour sur le congrès de l AHA 2017 Paul Poirier MD, PhD, FRCPC, FACC, FAHA, FCCS Professeur Faculté de pharmacie Université Laval Responsable du programme de prévention/réadaptation cardiaque Canagliflozin

More information

Cardiovascular Diseases in CKD

Cardiovascular Diseases in CKD 1 Cardiovascular Diseases in CKD Hung-Chun Chen, MD, PhD. Kaohsiung Medical University Taiwan Society of Nephrology 1 2 High Prevalence of CVD in CKD & ESRD Foley RN et al, AJKD 1998; 32(suppl 3):S112-9

More information

Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls

Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Assessing Blood Pressure for Clinical Research: Pearls & Pitfalls Anthony J. Viera, MD, MPH, FAHA Department of Family Medicine Hypertension Research Program UNC School of Medicine Objectives Review limitations

More information

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University

More information

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention,

More information

Mineral and bone disorder (MBD) affects the majority

Mineral and bone disorder (MBD) affects the majority Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis Patients Mark D. Danese,* Vasily Belozeroff, Karen Smirnakis, and Kenneth J. Rothman *Outcomes Insights, Inc., Newbury Park, California;

More information

The Seventh Report of the Joint National Commission

The Seventh Report of the Joint National Commission The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak, MD; Tom Greene, PhD; Xuelei Wang,

More information

Objectives. Describe results and implications of recent landmark hypertension trials

Objectives. Describe results and implications of recent landmark hypertension trials Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival

The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,

More information

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION*

ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Progress in Clinical Medicine 1 ANTIHYPERTENSIVE DRUG THERAPY IN CONSIDERATION OF CIRCADIAN BLOOD PRESSURE VARIATION* Keishi ABE** Asian Med. J. 44(2): 83 90, 2001 Abstract: J-MUBA was a large-scale clinical

More information

Chapter 11 Blood pressure profile of prevalent patients receiving dialysis in the UK in 2007: national and centre-specific analyses

Chapter 11 Blood pressure profile of prevalent patients receiving dialysis in the UK in 2007: national and centre-specific analyses Blood pressure profile of prevalent patients receiving dialysis in the UK in 07: national and centre-specific analyses Janice Harper a, Johann Nicholas b, Daniel Ford c, Anna Casula c and Andrew J Williams

More information

Aetiology versus Prediction - correct for Confounding? Friedo Dekker ERA-EDTA Registry / LUMC

Aetiology versus Prediction - correct for Confounding? Friedo Dekker ERA-EDTA Registry / LUMC Aetiology versus Prediction - correct for Confounding? Friedo Dekker ERA-EDTA Registry / LUMC Aetiology Study effect of a risk factor on an outcome Consider potential confounding: other risk factor for

More information

Biomarkers in the Assessment of Congestive Heart Failure

Biomarkers in the Assessment of Congestive Heart Failure Biomarkers in the Assessment of Congestive Heart Failure Mid-Regional pro-adrenomedullin (MR-proADM) vs BNP & NT-proBNP as Prognosticator in Heart Failure Patients: Results of the BACH Multinational Trial

More information

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease D. Dallmeier 1, D. Rothenbacher 2, W. Koenig 1, H. Brenner

More information